Back

Hana Zelenkova

Hana Zelenkova

Founder, President: Slovak Society for Aesthetic & Cosmetic Dermatology
President of the Traditional International Dermaparty congress
DOST Svidnik, Slovakia

Title: Therapy with immune modulators (cyclosporine A) in dermatology (focusing on psoriasis, atopic eczema, allergic vasculitis, and chronic urticaria)

Biography

Hana Zelenková has been active in Dermatovenerology since 1973. Since 2000 she has been directing her own Private Clinic of Dermatovenereology. Orientation: Psoriasis vulgaris, atopic dermatitis, mycosis, aesthetic dermatology (anti aging medicine, keloid and scar). She has given more than 650 expert lectures in Slovak Republic as well as abroad, and has 420 scientific publications. She is the Founder and President of the Slovak Society for Aesthetic and Cosmetic Dermatology President of the traditional international DERMAPARTY congress.

Abstract

Cyclosporine A is an immunosuppressant cyclic polypeptide isolated from the Tolypocladium inflatum fungus. Indications: organ transplantations (kidney, liver, heart, lungs, pancreas, skin), bone marrow transplantations, autoimmune disorders, and selected dermatoses such as psoriasis or AD. The indication window is opening wider and wider. In most indications the recommended administration form is oral. Transplanted patients require routine monitoring of CyA levels in blood. In non-transplantation indications the monitoring of CyA levels in blood is of limited importance, only. In dermatology, Cyclosporine A is administered in three groups of indications: Group I – dermatoses treated with maximum efficacy drugs, where CyA represents an extraordinarily effective first choice drug. Group II - dermatoses with the possibility to administer an alternative systemic drug based on the therapist’s choice, however, with CyA still being the best choice. Group III - other dermatoses (with individual therapy assessment due to presumed disease development and possible relapses). The window of indications is still widening (chronic urticaria, vitiligo). The commencement of CyA therapy in line I – III requires erudition and experience. In patients with severe dermatoses CyA therapy rapidly improves the local finding and radically improves the quality of patients’ life. Cyclosporine A must be only administered according to evidence based medicine!!!

Speaker Presentations

Speaker PDFs

Speaker PPTs

Download PPT